Efficacy and Safety of Aidi Injection as an Adjuvant Therapy on Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of included trials.

Trials	Design	No. of cases T/C	Age T/C	KPS T/C	TNM	Treatment	Control	Outcomes
Yumeng [16]	RCT	24/26	55.08 ± 10.32/54.12 ± 10.75	86.25 ± 5.76/87.50 ± 5.52	I–IV	Aidi 100 ml/d/1–7 q 21d + CEF or CAF	CEF or CAF	SAS, SDS, QLQC30, ORR, AEs
Weiming [13]	RCT	39/40	46.73 ± 14.2/45.98 ± 15.78	>50#	III-IV	Aidi 100 ml/d/1–8 q 21d + CEF	CEF	ICs, QoL, BMs, AEs
Yonghong [12]	RCT	64/64	46.7 ± 20.3	#	I–IV	Aidi 100 ml/d/1–8 q 21d + CEF	CEF	ICs, AEs
Liwang et al. [17]	RCT	78/62	52.5 (24∼76)/51.2 (20∼70)	#	I–IV	Aidi 100 ml/d/1–14 + CEF or CAF	CEF or CAF	ICs
Mei and Li [18]	RCT	23/23	52 (36∼64)	#	I–III	Aidi 100 ml/d/1–7 q 21d + CEF	CEF	VEGF
Sandi et al. [19]	RCT	26/22	42.27 ± 6.32/42.23 ± 6.7	84.23 ± 5.78/84.55 ± 5.96	IIA–IIIC	Aidi 60 ml/d/1–4 q 14d + TC-P	TC-P	ORR, QoL, AEs
Chuanhui et al. [20]	RCT	24/28	57.21 ± 3.52/55.66 ± 3.43	#	IIB–IIIB	Aidi 80 ml/d/1–15 q 21d + TAC	TAC	ORR, ICs
Zhuorong et al. [21]	RCT	30/26	42.47 ± 7.85/42.54 ± 8.10	83.67 ± 6.15/84.62 ± 5.82	II-III	Aidi 60 ml/d/1–4 q 14d + AC-T	AC-T	ORR, QoL, AEs
Xiangguo and Lin [22]	RCT	28/20	36.2 ± 3.6/37.5 ± 4.2	72.87 ± 4.69/71.89 ± 5.03	I–IIIA	Aidi 100 ml/d/1–10 q 21d + CTF	CTF	ORR, QoL, AEs
Ling and Xiaoge [23]	RCT	44/44	42 (32∼63)/48 (31∼65)	#	I–IV	Aidi 100 ml/d/1–15 q 28d + NP	NP	ORR, DCR, TTP, AEs
Xiangqiand Shaobo [24]	RCT	32/20	46.2 ± 2.6/44.5 ± 3.2	70.78 ± 4. 40/71.19 ± 4.53	I–IIIA	Aidi 100 ml/d/1–10 q 21d + CEF	CEF	ORR, QoL, AEs
Wenjuan [25]	RCT	30/30	48.4/47.6	#	III-IV	Aidi 100 ml/d/1–10 q 21d + CAF	CAF	ORR, ICs, QoL
Zhenzhen [26]	RCT	50/50	45	#	II-III	Aidi 100 ml/d/1–14 q 21d + CAF	CAF	ORR, ICs, QoL, AEs
Ling [27]	RCT	31/28	54.2 (32∼69)/53.5 (31∼70)	#	II–IV	Aidi 50 ml/d/1–15 q 21d + NT	NT	ORR, ICs, QoL, AEs

BC: breast cancer; T: treatment; C: control; ORR: overall response rate; DCR: disease control rate; TTP: time to progression; AE: adverse events; QoL: quality of life; BM: blood marker; IC: immune cell; SAS: Self-Rating Anxiety Scale; SDS: Self-Rating Depression Scale; QLQC30: Quality Of Life Questionnaire Core 30; CF: cardiac function; ECG: electrocardiogram; CK: creatinine kinase; CEF: cytoxan, epirubicin, and 5-fluorouracil; CAF: cytoxan, adriamycin, and 5-fluorouracil; TC-P: theprubicin, cytoxan, and paclitaxel; TAC: theprubicin, adriamycin, and cytoxan; AC-T: adriamycin, cytoxan, and theprubicin; CTF: cytoxan, theprubicin, and 5-fluorouracil; NT: navelbine and theprubicin. Data were expressed as medium and interquartile range (IQR). #Details not reported.